BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M

BIOMARIN PHARMACEUTICAL INC

Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.
Amicus had $214.0M cash, $392.7M long-term debt, and $2.77B accumulated deficit as of Dec 31, 2025.
BioMarin acquired Amicus for $14.50/share in cash, closing April 27, 2026; this filing provides audited financials and pro forma.
Amicus revenue concentrated: one customer accounted for 24% of 2025 net product sales.
Pro forma condensed combined financials as of Dec 31, 2025 included in Exhibit 99.2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.